However, its broader regulatory status is complex - FDA has raised regulatory and safety concerns regarding certain BPC-157-related bulk substances used in compounding contexts, and classifications may vary by use, jurisdiction, and product category
The primary preclinical evidence comes from mouse studies showing reduced body weight and adipose mass in diet-induced obese mice (2018), improved grip strength in aged mice (2024), and beneficial microbiome changes when combined with caloric restriction (2022)
While both peptides are frequently discussed in regenerative research, GHK-Cu vs BPC-157 is not a simple better or worse comparison
In WT and obese animals, AOD9604 reduces fat mass, increases 3-AR expression, enhances lipolysis, and stimulates energy expenditure and fat oxidation